Goto Thread: PreviousNext
Goto: Forum ListMessage ListNew TopicSearchLog In
Monoclonal antibodies market for cancers to double
Posted by: admin (IP Logged)
Date: January 24, 2014 02:46PM

Due to favorable market conditions in terms of US pricing structures and the anticipated approval of a number of late-stage pipeline drugs, the market value for monoclonal antibodies (mAbs) in gastric and esophageal cancer treatment is expected to double by 2019, according to a new report from business intelligence provider GBI Research.

The company’s latest report forecasts that the market for mAbs in gastric cancer will grow from $256m in 2012 to $501m by 2019, at a Compound Annual Growth Rate (CAGR) of 10%, while the mAbs market for esophageal cancer is expected to climb from $137m in 2012 to $265m by 2019, at a CAGR of 9.9%.

Currently, there is only one mAb — herceptin — available for the two indications. Primarily marketed for breast cancer, herceptin gained approval from the US Food and Drug Administration for the treatment of gastric and esophageal cancers in 2010. However, its patent is expected to expire in the European Union in 2014 and in the US by 2019.

Dominic Trewartha, Analyst for GBI Research, says: “Overall, herceptin is able to improve survival times to a significant extent when compared with chemotherapy alone, without adding a substantial amount of side effects or safety concerns in human epidermal growth factor Receptor-2 (HER-2) positive patients. However, its efficacy is not sufficient to bring about a sustained remission in most cases of advanced disease, or to replace conventional chemotherapy completely in earlier stages.”

According to GBI Research, the pipeline for both indications is moderate, with 33 mAbs for gastric cancer and eight for esophageal cancer. The late-stage pipelines also include a number of novel drugs that have shown some clinical and commercial potential. However, none of these products are anticipated to offer significant improvements over existing therapies.

“There is still a need for stronger products with superior efficacy to treat both gastric and esophageal cancers in the metastatic and early settings periods. Also, with a large HER-2 negative patient population that is not eligible for treatment with Herceptin, there is a strong unmet need and opportunity for therapies that are effective in these patients, including those who overexpress HER-2,” Trewartha concludes.

Re: Monoclonal antibodies market for cancers to double
Posted by: Seth Girardin (IP Logged)
Date: November 09, 2018 06:24AM


Re: Monoclonal antibodies market for cancers to double
Posted by: zhangmeng55 (IP Logged)
Date: April 04, 2019 10:35AM


Re: Monoclonal antibodies market for cancers to double
Posted by: happyleila (IP Logged)
Date: May 31, 2019 09:46AM


Re: Monoclonal antibodies market for cancers to double
Posted by: happyleila (IP Logged)
Date: June 20, 2019 06:31AM


Re: Monoclonal antibodies market for cancers to double
Posted by: BenjaminMiller (IP Logged)
Date: July 15, 2019 01:13PM


Re: Monoclonal antibodies market for cancers to double
Posted by: Laura Gerlach (IP Logged)
Date: July 15, 2019 04:50PM


Re: Monoclonal antibodies market for cancers to double
Posted by: Laura Gerlach (IP Logged)
Date: July 15, 2019 04:50PM


Re: Monoclonal antibodies market for cancers to double
Posted by: Laura Gerlach (IP Logged)
Date: July 15, 2019 04:51PM

nice



Edited 1 time(s). Last edit at 07/16/2019 10:08AM by Laura Gerlach.

Re: Monoclonal antibodies market for cancers to double
Posted by: zhangmeng55 (IP Logged)
Date: July 25, 2019 09:11PM


Re: Monoclonal antibodies market for cancers to double
Posted by: zhangmeng55 (IP Logged)
Date: August 08, 2019 01:38PM


Re: Monoclonal antibodies market for cancers to double
Posted by: zhangmeng55 (IP Logged)
Date: August 12, 2019 04:53AM




Sorry, only registered users may post in this forum.
This forum powered by Phorum.